opc 12759 has been researched along with Sicca Syndrome in 7 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
| Excerpt | Relevance | Reference |
|---|---|---|
| " No difference in the incidence of adverse events was seen between the two groups, confirming the safety of rebamipide." | 2.74 | Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. ( Kawakami, A; Koni, I; Nishinarita, M; Nishiyama, S; Ohta, S; Oka, H; Sawada, S; Sugai, S; Sugiyama, E; Takahashi, H; Takei, M; Umehara, H; Yamaji, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Jin-Sil, P | 1 |
| Sun-Hee, H | 1 |
| SeungCheon, Y | 1 |
| JeongWon, C | 1 |
| Kyung-Ah, J | 1 |
| Mi-La, C | 1 |
| Sung-Hwan, P | 1 |
| Shoji, J | 1 |
| Inada, N | 1 |
| Tomioka, A | 1 |
| Yamagami, S | 1 |
| Arakaki, R | 2 |
| Eguchi, H | 1 |
| Yamada, A | 1 |
| Kudo, Y | 1 |
| Iwasa, A | 1 |
| Enkhmaa, T | 1 |
| Hotta, F | 1 |
| Mitamura-Aizawa, S | 1 |
| Mitamura, Y | 1 |
| Hayashi, Y | 2 |
| Ishimaru, N | 2 |
| Arimoto, A | 1 |
| Kitagawa, K | 1 |
| Mita, N | 1 |
| Takahashi, Y | 1 |
| Shibuya, E | 1 |
| Sasaki, H | 1 |
| Kapoor, S | 1 |
| Sugai, S | 1 |
| Takahashi, H | 1 |
| Ohta, S | 1 |
| Nishinarita, M | 1 |
| Takei, M | 1 |
| Sawada, S | 1 |
| Yamaji, K | 1 |
| Oka, H | 1 |
| Umehara, H | 1 |
| Koni, I | 1 |
| Sugiyama, E | 1 |
| Nishiyama, S | 1 |
| Kawakami, A | 1 |
| Kohashi, M | 1 |
2 trials available for opc 12759 and Sicca Syndrome
| Article | Year |
|---|---|
Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjögren's syndrome-associated dry eyes.
Topics: Adult; Aged; Aged, 80 and over; Alanine; CA-125 Antigen; Female; Gene Expression Regulation; Humans; | 2020 |
Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial.
Topics: Aged; Alanine; Anti-Inflammatory Agents; Double-Blind Method; Eating; Female; Humans; Male; Middle A | 2009 |
5 other studies available for opc 12759 and Sicca Syndrome
| Article | Year |
|---|---|
Immune modulation by rebamipide in a mouse model of Sjogren's syndrome via T and B cell regulation.
Topics: Alanine; Animals; B-Lymphocytes, Regulatory; Cytokines; Disease Models, Animal; Immunomodulation; Mi | 2019 |
Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren's syndrome.
Topics: Administration, Ophthalmic; Alanine; Animals; Anti-Inflammatory Agents; Cells, Cultured; Disease Mod | 2014 |
Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antibodies, Antinuclear; Antioxidants; Autoantibodies; Eyel | 2014 |
Sjogren's syndrome: promising, new treatment options besides nizatidine.
Topics: Alanine; Antioxidants; Flax; Histamine H2 Antagonists; Humans; Nizatidine; Plant Preparations; Quino | 2009 |
Effective treatment with oral administration of rebamipide in a mouse model of Sjögren's syndrome.
Topics: Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Autoantibodies; Cell Division; Cyt | 2008 |